10/593133

IB 05708697

WO 2005/090313

PCT/IB2005/000597

142

#### **CLAIMS**

1. A compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,

wherein:

10 R¹ represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkanoyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl and pentafluorothio;

R<sup>2</sup> represents)hydregen(,halo, cyano, nitro,)C<sub>1-6</sub> alkyl(,C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkynyl, -S(O)<sub>n</sub>C<sub>1-6</sub> alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub> haloalkyl, -(C<sub>0-3</sub> alkylene)-C<sub>3-8</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, phenyl, het, -(C<sub>0-3</sub> alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub> alkylene)-C(O)NR<sup>a</sup>R<sup>b</sup> or -(C<sub>0-3</sub> alkylene)-N(R<sup>c</sup>)C(O)R<sup>6</sup>;

20  $\mathsf{R}^3 \text{ represents } \mathsf{C}_{1\text{-6}} \text{ alkyl}, \; \mathsf{C}_{1\text{-6}} \text{ haloalkyl}, \; \mathsf{C}_{2\text{-6}} \text{ alkenyl}, \; \mathsf{C}_{2\text{-6}} \text{ haloalkenyl}, \; \mathsf{-}(\mathsf{C}_{0\text{-3}} \text{alkylene}) - \mathsf{C}_{3\text{-8}} \text{ cycloalkyl} \; , \; \; \mathsf{-}(\mathsf{C}_{1\text{-3}} \text{alkylene}) - \mathsf{S}(\mathsf{O})_n \mathsf{C}_{1\text{-6}} \text{haloalkyl}, \; \; \mathsf{-}(\mathsf{C}_{0\text{-3}} \text{alkylene}) - \mathsf{S}(\mathsf{O})_n \mathsf{C}_{1\text{-6}} \text{haloalkyl}, \; \; \mathsf{-}(\mathsf{C}_{0\text{-3}} \text{alkylene}) - \mathsf{S}(\mathsf{O})_n \mathsf{C}_{1\text{-6}} \text{haloalkyl}, \; \; \mathsf{-}(\mathsf{C}_{0\text{-3}} \text{alkylene}) - \mathsf{S}(\mathsf{O})_n \mathsf{C}_{1\text{-6}} \text{haloalkyl}, \; \; \mathsf{-}(\mathsf{C}_{2\text{-3}} \text{alkenylene}) - \mathsf{D}(\mathsf{C}_{2\text{-3}} \text{alkenylene})$ 

 $R^4$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$ haloalkyl, -( $C_{0-3}$ alkylene)- $R^7$  or -( $C_{1-3}$ alkylene)- $R^8$ ;

or R<sup>3</sup> and R<sup>4</sup> taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

**25**.

PCT/IB2005/000597

143

 $R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkoxy,  $C_{1-6}$  haloalkoxy,  $C_{1-6}$ 

5 R<sup>6</sup> represents C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

R<sup>7</sup> represents C<sub>3-8</sub>cycloalkyl, -S(O)<sub>n</sub>R<sup>9</sup>, phenyl, het, -CO<sub>2</sub>R<sup>6</sup> or C(O)N(R<sup>8</sup>)R<sup>b</sup>;

R<sup>8</sup> represents hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, cyano, -N(R<sup>8</sup>)R<sup>5</sup> or -O-C(O)R<sup>6</sup>;

 $R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}$  cycloalkyl,  $-N(R^a)R^b$ , phenyl or het;

R<sup>10</sup> represents hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

15 R<sup>11</sup> represents hydrogen, hydroxy, C<sub>1-3</sub>alkoxy, -N(R<sup>a</sup>)R<sup>b</sup>, phenyl, het or C<sub>3-8</sub>cycloalkyl, with the proviso that -N=C(R<sup>10</sup>)(C<sub>0-5</sub>alkylene)-R<sup>11</sup> is not -N=CH<sub>2</sub>;

R<sup>12</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl or C<sub>1-6</sub> haloalkenyl;

20 R<sup>13</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl C<sub>3</sub>.

8cycloalkyl, phenyl, het, -(C<sub>1-6</sub>alkylene)-R<sup>14</sup>, -C(O)<sub>p</sub>R<sup>15</sup> or -CON(R<sup>16</sup>)(C<sub>1-6</sub>alkylene)-R<sup>17</sup>;

 $R^{14}$  represents hydroxy,  $C_{1-3}$ alkoxy,  $C_{1-3}$ haloalkoxy,  $C_{3-6}$ cycloalkyl, phenyl, het or -  $N(R^a)R^b$ ;

 $R^{15}$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl or -( $C_{1-6}$ alkylene)- $C_{1-3}$ alkoxy;

R<sup>16</sup> represents hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

30 R<sup>17</sup> represents hydrogen or N(R<sup>a</sup>)R<sup>b</sup>;

 $R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents -( $C_{0-3}$ alkylene)-- $C_{3-8}$  cycloalkyl, -( $C_{0-3}$ alkylene)--phenyl or -( $C_{0-3}$ alkylene)--het, or together  $R^a$  and  $R^b$  form a 4- to 7-

PCT/IB2005/000597

. 144

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub>haloalkoxy;

R<sup>c</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub>alkylene)—C<sub>3-6</sub> cycloalkyl, -(C<sub>0-3</sub>alkylene)—phenyl or -(C<sub>0-3</sub>alkylene)—het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a tour- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub> alkoxycarbonyl and NR<sup>a</sup>R<sup>b</sup>;

where C<sub>3-8</sub>cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-8</sub>haloalkenyl, hydroxy, C<sub>1-6</sub>alkoxy and C<sub>1-6</sub>haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

30

2. A compound according to claim 1, wherein R<sup>1</sup> is a phenyl group which bears chloro substituents at the 2- and 6-positions, and a substitutent at the 4-position selected from trifluoromethyl, diffuoromethoxy, trifluoromethoxy, trifluoromethylthio and pentafluorothio.

WO 2005/090313

PCT/IB2005/000597

- 145
- 3. A compound according to claim 1 or 2, wherein R<sup>2</sup> is selected from hydrogers cyano, C<sub>1-6</sub> haloalkyl, C<sub>3-8</sub> cycloalkyl, e.g. cyclopropyl, C<sub>1-6</sub> alkanoyl and -C(O)N(R<sup>a</sup>)R<sup>b</sup>.
- 5 4. A compound according to claim 3, wherein R<sup>2</sup> is cyano.
  - 5. A compound according to any one of claims 1-4, wherein  $R^3$  is selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $-(C_{1-3}$ alkylene)- $S(O)_nC_{1-6}$ alkyl,  $-N(R^a)R^b$ ,  $C_{1-6}$  alkanoyl,  $-N(R^a)CO_2R^6$ , phenyl, optionally substituted by one or more halo, and benzyl.
  - 6. A compound according to claim 5, wherein R3 is methyl.
- A compound according to any one of claims 1-6, wherein R<sup>4</sup> is selected from hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-8</sub> cycloalkyl, cyanomethyl, 2-hydroxyethyl, -(C<sub>1-2</sub>alkylene)-het, -(C<sub>0-3</sub>alkylene)-phenyl, -(C<sub>0-1</sub>alkylene)-S(O)<sub>n</sub>R<sup>9</sup>, -(C<sub>1-3</sub>alkylene)-O-C(O)R<sup>8</sup>, -(C<sub>1-3</sub>alkylene)-C(O)N(R<sup>8</sup>)R<sup>b</sup> and -CO<sub>2</sub>R<sup>8</sup>.
- 8. A compound according to claim 7, wherein R4 is selected from hydrogen, methyl. trifluoromethyl. 2,2-difluoroethyl. 2,2,2-trifluoroethyl, ethyl, methylsulfonyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, aminosulfonyl, 20 dimethylaminosulfonyl, methylsulfonymethyl, cyclopropyl, cyclopropylmethyl, 1-(trifluoromethyl)cyclopropylmethyl, cyanomethyl, methoxycarbonyl, triazolylethyl, pyrimidin-4-ylmethyl, 1,2,4-oxadiazol-3-ylmethyl, pyrazol-3-ylmethyl, imidazol-2-yl, 5-methyl-isoaxazol-3-ylmethyl, 2-pyridin-4-ylethyl, aminocarbonylmethyl, benzyl and 4-fluorobenzyl. 25
  - 9. A compound according to any one of claims 1-8, wherein  $R^5$  is selected from hydrogen, halo,  $C_{1-6}$  alkoxy, -N=C(H) $R^{11}$ , where  $R^{11}$  is ethoxy, N,N-dimethyl or phenyl, and -N $R^{12}$  $R^{13}$ .
  - 10. A compound according to claim 9, wherein R<sup>5</sup> is amino.
  - 11. A compound of formula (I) selected from:

30.

PCT/IB2005/000597

- N-{5-amino-3-cyano-1-{2,6-dichloro-4pentafluorothiophenyl}-1H-pyrazol-4-yl}-N-(2,2-difluoroethyl)methanesulfonamide;
- N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-1,1,1-trifluoro-N-methylmethanesulfonamide;
- 5 N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-3,4-difluorobenzenesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-N-(cyclopropylmethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-
- 10 (cyanomethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl}-1*H*-pyrazol-4-yl}-N-(pyridin-2-ylmethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-N-benzylmethanesulfonamide;
- 15 N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-{2-(dimethylamino)ethyl]methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-1-(methylsulfonyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(2-
- 20 hydroxyethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-N-[(methylthio)methyl]methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-N-(methylsulfonyl)cyclopropanesulfonamide;
- 25 N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1 H-pyrazol-4-yl}-N[(dimethylamino)sulfonyl]methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl}-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;
  - $N-\{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1~H-pyrazol-4-(trifluoromethyl)phenyl[-1~H-pyrazol-4-(trifluoromethyl)phenyl[-1~H-pyrazol-4-(trifluoromethyl)phenyl[-1~H-pyrazol-4-(trifluoromethyl)p$
- 30 yl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1//-pyrazol-4-yl}-1-phenylmethanesulfonamide;
  - (E)-N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1 H-pyrazol-4-yl}-2-phenylethylenesulfonamide;

#### PCT/IB2005/000597

147

N-[5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxidoisothiazolidin-2-yl)-1*H*-pyrazole-3-carbonitrile;

- 5 N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl]-1 H-pyrazol-4-yl}-1,1,1-trifluoro-N-methylmethanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl}-1 H-pyrazol-4-yl}-N-(cyclopropylmethyl)-1,1,1-trifluoromethanesulfonamide;
- *N*-{5-amino-3-cyano-1-{2;6-dichloro-4-(trifluoromethyl)phenyl}-1 *H*-pyrazol-4-yl}-*N*-{2,2,2-10 trifluoroethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl}-1 H-pyrazol-4-yl}-1,1,1-trifluoro-N-(methylsulfonyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1 H-pyrazol-4-yl}-N-cyclobutyl-1,1,1-trifluoromethanesulfonamide;
- N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N- (methylsulfonyl)methanesulfonamide;
  - N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1,1,1-trifluoro-*N*-methylmethanesulfonamide;
  - N-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-
- 20 (methylsulfonyl)methanesulfonamide;
  - N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;
  - N-{3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl]-1 H-pyrazol-4-yl}methanesulfonamide;
- 25 N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1 H-pyrazol-4-yl}-N-{2,2,2-triffuoroethyl}methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1 H-pyrazol-4-yl}-N-{2-(1 H-
- 30 1,2,4-triazol-1-yt)ethyt]methanesulfonamide;
  - 5-amino-4-[bis(methylsulfonyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazole-3-carboxamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;

PCT/IB2005/000597

148

N-{3-acetyl-5-amino-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

- 5 N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;
  - $N-\{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1$ *H*-pyrazol-4-yl $\}-N-\{[1-(trifluoromethyl)cyclopropyl]methyl<math>\}$ methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothlophenyl}-1H-pyrazol-4-yl}-N-
- (methylsulfonyl)ethanesulfonamide; methyl 5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl(methylsulfonyl)carbamate;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1 H-pyrazol-4-yl}-N-methylmethanesulfonamide;
- 15 N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-N-{2-fluoroethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1 H-pyrazol-4-yl]-N-(1,2,4-oxadiazol-3-ylmethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyf]-1 H-pyrazol-4-yf}-N-
- 20 (methylsulfonyl)glycinamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl)-N-(1H-pyrazol-3-ylmethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-(2,2,3,3,3-pentafluoropropyl)methanesulfonamide;
- 25 N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1 H-pyrazol-4-yl}-N-{2-pyrrolidin-1-ylethyl}methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-(2-morpholin-4-ylethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1 H-pyrazol-4-yl}-N-{(1-
- 30 methyl-1*H*-imidazol-2-yl)methyl]methanesulfonamide;
  N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-[(5-methylisoxazol-3-yl)methyl]methanesulfonamide;
  - [{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}(methylsulfonyl)amino]methyl pivalate;

PCT/IB2005/000597

149

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-ethylmethanesulfonamide;

N-{5-amino-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-N-benzylmethanesulfonamide;

- 5 N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-(4-fluorobenzyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1-(methylsulfonyl)ethanesulfonamide;
  - N-{5-amino-1-[2-chloro-4-pentafluorothio-phenyl]-3-cyano-1H-pyrazol-4-yl}-N-
- (methylsulfonyl)methanesulfonamide;
   5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(1,1-dioxido-1,2-thiazinan-2-yl)-1*H*-pyrazole-3-carbonitrile;
  - N-{5-(benzylamino)-3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;
- N-{3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino}-1H-pyrazol-5-yl}-2-methoxyacetamide; ethyl 4-[bis(methylsulfonyl)amino}-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-5-ylimidoformate;
  - N-{3-cyano-5-[(cyclopropylmethyl)amino]-1-[2,6-dichloro-4-pentaliuorothiophenyl]-1H-
- 20 pyrazol-4-yl}methanesulfonamide;
  - N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino}-1 H-pyrazol-5-yl}acetamide;
  - N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-methoxy-1*H*-pyrazol-4-yl}methanesulfonamide;
- N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(methylamino)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;
  - N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[(dimethylamino)methylene]amino}-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;
- N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[2-(dimethylamino)ethyl]amino}1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;
  N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-pyrrolidin-1-ylethyl)amino]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

PCT/IB2005/000597

150

N-{3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-5-[(2-morpholin-4-ylethyl)amino}-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-5-{(2-piperidin-1-ylethyl)amino}-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

- 5 N-{5-amino-3-cyclopropyl-1-{2,6-dichloro-4-pentafluorothiophenyl}-1H-pyrazol-4-yl}-N- (methylsulfonyl)methanesulfonamide;
  - A-(5-amino-1-[2,6-dichloro-4-pontafluorothiophenyl]-1// pyrazol-4---yl]methanesulfonamide(

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(pyridin-4-ylmethyl)amino]-1H-

- 10 pyrazol-4-yl}methanesulfonamide;
  - tert-butyl ({5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl}-1*H*-pyrazol-4-yl}amino)sulfonylcarbamate;
  - N-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1 H-pyrazol-4-yl}-N-(2-pyridin-4-ylethyl)methanesulfonamide;
- N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-(pyrazin-2-ylmethyl)methanesulfonamide;
  - $N-\{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl\}-N-[(6-aminopyridin-3-yl)methyl]methanesulfonamide;$
  - N-{3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-1 H-pyrazol-4-yl}-2-oxo-N-{2,2,2-
- 20 trifluoroethyl)propane-1-sulfonamide;
  - N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[3-(dimethylamino)propyl]amino]-1H-pyrazol-4-yl)-N-(2,2,2-trifluoroethyl)methanesulfonamide;
  - N-[3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1H-
- 25 pyrazol-4-yi}-N-(2,2,2-trifluoroethyl)methanesulfonamide;
  - N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-sulfamide; N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl}-1H-pyrazol-4-yl}-4-fluoro-N-(methylsulfonyl)benzenesulfonamide;
  - Al IE amino Common 4 (O.C. diables of this incompleted by honey) 4 ()
- N-{5-amino-3-cyano-1-{2,6-dichloro-4-(trifluoromethyl)phenyl}-1*H*-pyrazol-4-yl}-2,4-difluoro-N-(methylsulfonyl)benzenesulfonamide;
  - methyl 3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl}-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-ylcarbamate;
    - N-{5-({[(2-aminoethyl)amino]carbonyl}amino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide;

WO 2005/090313

PCT/LB2005/000597

151

trifluoroacetate satt of N-{5-[(2-azetidin-1-ylethyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide; N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{{(2,4-dihydroxyphenyl)methylene]amino}-1H-pyrazol-4-yl)-N-(2,2,2-

- 5 trifluoroethyl)methanesulfonamide;
  - $N-\{5-chloro-3-cyano-1-\{2,6-dichloro-4-pentafluorothiophenyl]-1$   $H-pyrazol-4-yl\}-N-\{2,2,2-trifluoroethyl\}$  methanesulfonamide; or
  - N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[3-(dimethylamino)ethyl]amino}-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;
- 10 or a pharmaceutically acceptable salt or solvate thereof.
  - 12. A pharmaceutical or veterinary composition comprising a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, and a suitable excipient or carrier.

13. A compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, for use in medical therapy.

20 \_veterinarily acceptable salt or solvate thereof, in the manufacture of a human or animal-parasiticidal medicament(

>15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically acceptable amount of compound according to any one claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof.

<del>₩0 2005/090313</del>(

152 142 \<del>PCT/IB2005/000597 (</del>

14. Use of a compound of formula (1)

5 acceptable salt or solvate thereof,

wherein:

10 R<sup>1</sup> represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, -S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl and pentafluorothio;

15 R<sup>2</sup> represents hydrogen, halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-6</sub> haloalkynyl, C<sub>2-6</sub> haloalkynyl, -S(O)<sub>n</sub>C<sub>1-6</sub> alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-8</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, phenyl, het, -(C<sub>0-3</sub>alkylene)-N(R<sup>6</sup>)R<sup>6</sup>, -(C<sub>0-3</sub>alkylene)-C(O)NR<sup>6</sup>R<sup>6</sup> or -(C<sub>0-3</sub>alkylene)-N(R<sup>6</sup>)C(O)R<sup>6</sup>;

 $R^3$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl, -( $C_{0-3}$ alkylene)- $C_{3-8}$  cycloalkyl , -( $C_{1-3}$ alkylene)-S(O),  $C_{1-6}$ alkyl, -( $C_{1-3}$ alkylene)-S(O),  $C_{1-6}$ haloalkyl, -( $C_{0-3}$ alkylene)-het, -( $C_{2-3}$ alkylene)-het, -( $C_{2-3}$ alkenylene)-het, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl or -N( $R^c$ )CO<sub>2</sub> $R^6$ ;

 $R^4$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$ haloalkyl, -( $C_{0.3}$ alkylene)- $R^7$  or -( $C_{1.3}$ alkylene)- $R^8$ ;

or R<sup>3</sup> and R<sup>4</sup> taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

25 ·

25

### WO 2005/09031



<del>>CT/IB2005/000591</del><

 $R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkoxy,  $C_{1-6}$  haloalkoxy,  $C_{1-6}$ 

5 R<sup>8</sup> represents C<sub>1-8</sub> alkyl or C<sub>1-6</sub> haloalkyl;

R<sup>7</sup> represents C<sub>3-8</sub>cycloalkyl, -S(O)<sub>n</sub>R<sup>9</sup>, phenyl, het, -CO<sub>2</sub>R<sup>6</sup> or C(O)N(R<sup>a</sup>)R<sup>b</sup>;

R<sup>8</sup> represents hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, cyano, -N(R<sup>a</sup>)R<sup>b</sup> or -O-C(O)R<sup>6</sup>;

 $R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}$  cycloalkyl,  $-N(R^a)R^b$ , phenyl or het;

R<sup>10</sup> represents hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

15 R<sup>11</sup> represents hydrogen, hydroxy, C<sub>1-3</sub>alkoxy, -N(R<sup>a</sup>)R<sup>b</sup>, phenyl, het or C<sub>3-8</sub>cycloalkyl, with the proviso that -N=C(R<sup>10</sup>)(C<sub>0-5</sub>alkylene)-R<sup>11</sup> is not -N=CH<sub>2</sub>;

R<sup>12</sup> represents hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-8</sub> alkenyl or C<sub>1-6</sub> haloalkenyl;

20 R<sup>13</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl C<sub>3-6</sub> ecycloalkyl, phenyl, het, -(C<sub>1-6</sub>alkylene)-R<sup>14</sup>, -C(O)<sub>0</sub>R<sup>15</sup> or -CON(R<sup>16</sup>)(C<sub>1-6</sub>alkylene)-R<sup>17</sup>;

 $R^{14}$  represents hydroxy,  $C_{1\cdot3}$ alkoxy,  $C_{1\cdot3}$ haloalkoxy,  $C_{3\cdot8}$ cycloalkyl, phenyl, het or -  $N(R^a)R^b$ :

R15 represents C1-6 alkyl, C1-6 haloalkyl or -(C1-6alkylene)-C1-3alkoxy;

R<sup>16</sup> represents hydrogen, C<sub>1-5</sub> aikyl or C<sub>1-6</sub> haloaikyl;

30 R<sup>17</sup> represents hydrogen or N(R<sup>a</sup>)R<sup>b</sup>;

 $R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents -( $C_{0-3}$ alkylene)- $C_{3-6}$  cycloalkyl, -( $C_{0-3}$ alkylene)-het, or together  $R^a$  and  $R^b$  form a 4- to 7-

JWO 2005/090313C

154

**≻**PCT/IB2005/000597⊀

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub>haloalkoxy;

 $R^c$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl, -( $C_{0-3}$  cycloalkyl, -( $C_{0-3}$  alkylene)—phenyl or -( $C_{0-3}$  alkylene)—het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyt;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  haloalkenyl,  $C_{1-6}$  haloalkenyl,  $C_{1-6}$  alkoxycarbonyl and  $NR^aR^b$ ;

where C<sub>3-8</sub>cycloalkyl may be optionally substituted by one or more groups independently selected from hato, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub>haloalkenyl, hydroxy, C<sub>1-6</sub>alkoxy and C<sub>1-6</sub>haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo/

30 in the manufacture of a humain or animal parasiticidal medica-

**>VO-2005/090312**(

155

PCT/IB2005/000597

- 15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically compatible amount of or x compound of formula (1) or a pharmaceutically, veterinarily or agriculturally
  - 5 acceptable salt or solvate thereof,

wherein:

10 R¹ represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, -S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl and pentafluorothio;

15 R<sup>2</sup> represents hydrogen, halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkynyl, C<sub>2-6</sub> haloalkynyl, -S(O)<sub>n</sub>C<sub>1-6</sub> alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-6</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, phenyl, het, -(C<sub>0-3</sub>alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub>alkylene)-C(O)NR<sup>a</sup>R<sup>b</sup> or -(C<sub>0-3</sub>alkylene)-N(R<sup>c</sup>)C(O)R<sup>6</sup>;

 $R^3$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $-(C_{0-3}$ alkylene)- $C_{2-6}$  cycloalkyl ,  $-(C_{1-3}$ alkylene)- $S(O)_nC_{1-6}$ alkylene)- $S(O)_nC_{1-6}$ haloalkyl,  $-(C_{0-3}$ alkylene)- $S(O)_nC_{1-6}$ haloalkyl,  $-(C_{0-3}$ alkylene)-het,  $-(C_{2-3}$ alkenylene)-phenyl,  $-(C_{0-3}$ alkylene)-het,  $C_{1-6}$  alkanoyl,  $C_{1-6}$  haloalkanoyl or  $-N(R^c)CO_2R^6$ ;

R<sup>4</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-R<sup>7</sup> or -(C<sub>1-3</sub>alkylene)-R<sup>8</sup>;

or R<sup>3</sup> and R<sup>4</sup> taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

20

25

)<del>WO 2005/090313</del>(

156

)<del>PCT/IB2005/000597</del> **〈** 

 $R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkoxy,  $C_{1-6}$  haloalkoxy,  $C_{1-6}$ 

5 R<sup>6</sup> represents C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

 $R^7$  represents  $C_{3-8}$  cycloalkyl,  $-S(O)_nR^9$ , phenyl, het,  $-CO_2R^6$  or  $C(O)N(R^8)R^b$ ;

 $R^{8}$  represents hydroxy,  $C_{1\text{-}6}$  alkoxy,  $C_{1\text{-}6}$  haloalkoxy, cyano, -N(R\*)R\* or -O-C(O)R\* ;

 $R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $-N(R^6)R^6$ , phenyl or het;

R<sup>10</sup> represents hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl;

15 R<sup>11</sup> represents hydrogen, hydroxy, C<sub>1-3</sub>alkoxy, -N(R<sup>a</sup>)R<sup>b</sup>, phenyl, het or C<sub>3-8</sub>cycloalkyl, with the proviso that -N=C(R<sup>10</sup>)(C<sub>0-5</sub>alkylene)-R<sup>11</sup> is not -N=CH<sub>2</sub>;

 $R^{12}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl or  $C_{1-6}$  haloalkenyl;

20 R<sup>13</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl C<sub>3-8</sub> ecycloalkyl, phenyl, het, -(C<sub>1-6</sub>alkylene)-R<sup>14</sup>, -C(O)<sub>p</sub>R<sup>15</sup> or -CON(R<sup>16</sup>)(C<sub>1-6</sub>alkylene)-R<sup>17</sup>;

 $R^{14}$  represents hydroxy,  $C_{1-3}$ alkoxy,  $C_{3-8}$ cycloalkyl, phenyl, het or -  $N(R^a)R^b$ ;

 $\mathsf{R}^{15}$  represents  $\mathsf{C}_{1\text{-}6}$  alkyl,  $\mathsf{C}_{1\text{-}6}$  haloalkyl or -( $\mathsf{C}_{1\text{-}6}$ alkylene)- $\mathsf{C}_{1\text{-}3}$ alkoxy;

R<sup>16</sup> represents hydrogen, C<sub>1-8</sub> alkyl or C<sub>1-8</sub> haloalkyl;

30 R<sup>17</sup> represents hydrogen or N(R<sup>8</sup>)R<sup>b</sup>;

 $R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents -( $C_{0-3}$ alkylene)- $C_{3-8}$  cycloalkyl, -( $C_{0-3}$ alkylene)-het, or together  $R^a$  and  $R^b$  form a 4- to 7-

)WO 2005/090313(



**PET/ID2005/000597** 

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub> haloalkoxy;

R<sup>c</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-8</sub> cycloalkyl, -(C<sub>0-3</sub>alkylene)-phenyl or -(C<sub>0-3</sub>alkylene)-het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

20

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub>haloalkenyl, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub>haloalkoxy, C<sub>1-6</sub> alkoxycarbonyl and NR<sup>a</sup>R<sup>b</sup>;

where  $C_{3-6}$ cycloalkyl may be optionally substituted by one or more groups independently selected from halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ haloalkyl,  $C_{1-6}$  alkenyl,  $C_{1-6}$ haloalkoxy, and  $C_{1-6}$ haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTO	GRAPHS
GRAY SCALE DOCUMENTS	
LINES OR MARKS ON ORIGINAL DOCU	MENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY	
OTHER:	24

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.